Senti Biosciences Secures $53 Million Series A to Build the Future of Gene and Cell-Based Therapies

Founded by pioneers in the field of synthetic biology, Senti Biosciences' platform enables the design of adaptive therapies for challenging diseases. Series A round led by prominent investment firm New Enterprise Associates (NEA) along with other top inves... Biopharmaceuticals, Venture Capital Senti Biosciences, synthetic biology
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news